z-logo
open-access-imgOpen Access
Effects of Somatostatin Analogs on a Growth Hormone-Releasing Hormone Secreting Bronchial Carcinoid,in Vivoandin VitroStudies
Author(s) -
Mandy van Hoek,
Leo J. Hofland,
Yolanda B. de Rijke,
Francien H. van Nederveen,
R.R. de Krijger,
P. M. van Koetsveld,
Steven W. J. Lamberts,
A. J. van der Lely,
Wouter W. de Herder,
Richard A. Feelders
Publication year - 2008
Publication title -
the journal of clinical endocrinology and metabolism
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.206
H-Index - 353
eISSN - 1945-7197
pISSN - 0021-972X
DOI - 10.1210/jc.2008-1712
Subject(s) - somatostatin , somatostatin receptor , acromegaly , endocrinology , medicine , octreotide , in vivo , somatostatin receptor 2 , growth hormone–releasing hormone , in vitro , hormone , biology , growth hormone , biochemistry , microbiology and biotechnology
A 56-yr-old woman presented with acromegaly, a pulmonary mass, and elevated levels of GHRH, GH, and IGF-I. Histological examination revealed a bronchial carcinoid with positive staining for GHRH. Somatostatin analogs (SAs) can play an important role in the treatment of neuroendocrine tumors, dependent on the somatostatin receptor subtype (sst) expression pattern. The sst pattern in bronchial carcinoids and effects of SAs have not been extensively investigated, particularly not for the recently developed universal SA SOM230 (Pasireotide) that has high affinity for sst1, 2, 3, and 5.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom